

**产品名称: SB408124**

**产品别名: SB-408124**

**生物活性:**

<b>Description</b>	SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively; exhibits 50-fold selectivity over OX2 receptor. IC50 Value: 57 nM(Ki) Target: OX1 Receptor in vitro: SB-408124 binds hypocretin type 1 receptor (HcrtR1) with pKi values of 7.57. Calcium mobilization studies shows that SB-408124 is a functional antagonist of the OX1 receptor with a affinity of approximately 50-fold selectivity over the OX2 receptor. A recent study indicates that pretreatment of primary cultures of rat astrocytes with SB-408124 before Orexin A administration significantly reduced the stimulatory action of Orexin A on both basal and forskolin-activated cAMP production. in vivo: SB-408124 (30 µg/10 µL, administered intracerebroventricularly) decreases Orexin-A induced water intake in Wistar rats. Intracerebroventricularly administered Orexin-A (30 µg/10 µL) blocks the vasopressin (VP) level increase induced by either histamine or 2.5% NaCl administration, and this blocking effect is moderated by pretreatment with SB-408124. Intracerebroventricular pretreatment with SB-408124 (50 mM, 5 µL/h) prevents Bicuculline (BIC)-induced increases in endogenous glucose production (EGP).																					
<b>In Vitro:</b>  DMSO : 50 mg/mL (140.30 mM; Need ultrasonic)  H <sub>2</sub> O : < 0.1 mg/mL (insoluble)	<table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent Concentration</th><th>Mass</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr></thead><tbody><tr><td>1 mM</td><td></td><td>2.8061 mL</td><td>14.0304 mL</td><td>28.0607 mL</td></tr><tr><td>5 mM</td><td></td><td>0.5612 mL</td><td>2.8061 mL</td><td>5.6121 mL</td></tr><tr><td>10 mM</td><td></td><td>0.2806 mL</td><td>1.4030 mL</td><td>2.8061 mL</td></tr></tbody></table>	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	1 mM		2.8061 mL	14.0304 mL	28.0607 mL	5 mM		0.5612 mL	2.8061 mL	5.6121 mL	10 mM		0.2806 mL	1.4030 mL	2.8061 mL
Preparing Stock Solutions	Solvent Concentration		Mass	1 mg	5 mg	10 mg																
	1 mM		2.8061 mL	14.0304 mL	28.0607 mL																	
5 mM		0.5612 mL	2.8061 mL	5.6121 mL																		
10 mM		0.2806 mL	1.4030 mL	2.8061 mL																		
<b>Solvent&amp;Solubility</b>  请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。  储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。  <b>In Vivo:</b>  请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶  1.请依序添加每种溶剂: 10% DMSO → 90% corn oil Solubility: ≥ 2.5 mg/mL (7.02 mM); Clear solution  此方案可获得 ≥ 2.5 mg/mL (7.02 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。  以 1 mL 工作液为例, 取 100 µL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 µL 玉米油中, 混合均匀。																						
	[1]. Morarthy SR, et al. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One. 2012;7(7):e39131. Epub 2012 Jul 2.  [2]. Melis MR, et al. Neuroendocrine regulatory peptide-1 and neuroendocrine regulatory peptide-2																					

**References**

- [1]. [influence differentially feeding and penile erection in male rats: sites of action in the brain](#).Regul Pept. 2012 Aug 20;177(1-3):46-52. Epub 2012 May 2.
- [3]. [Assisi L, et al. Expression and role of receptor 1 for orexins in seminiferous tubules of rat testis](#).Cell Tissue Res. 2012 Jun;348(3):601-7. Epub 2012 Mar 28.
- [4]. [Kis GK, et al. The osmotically and histamine-induced enhancement of the plasma vasopressin level is diminished by intracerebroventricularly administered orexin in rats](#).Pflugers Arch. 2012 Apr;463(4):531-6. Epub 2012 Feb 16.
- [5]. [Langmead et al \(2004\) Characterisation of the binding of \[<sup>3</sup>H\]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor](#). Br.J.Pharmacol. 141 340.



源叶生物